TP53 and neoplasm: In both non-small cell lung cancer cells and human hepatoma cells, NuRD complexes have been shown to exert deacetylation activity against the tumour suppressor TP53, which results in an increase in its degradation by MDM2 and a reduction in TP53-mediated cell growth arrest and apoptosis [43,44].